Company / Operating Cash Flow
Exelixis Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$884.3M
FY2025
5-year range
$209.0M / $884.3M
FY2021-FY2025
Trend
+26.3%
vs FY2024
Sector context
#22 of 216
Health Care
What the data says
Among 216 Health Care companies, Exelixis is in the top 10% for operating cash flow. Operating Cash Flow has increased for 3 consecutive years, from $209M in FY2022 to $884M in FY2025.
Based on SEC 10-K filings.
$884M in FY2025 with a 5-year CAGR of +33.4%. Top quartile in the Health Care sector.
Improved from $333M to $884M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- +61.7%
- 5-Year CAGR
- +33.4%
- 10-Year CAGR
- -
Sector benchmark
Top 10% in Health CareTop 10% of 216This company $884.3M Sector average $659.0M
▼
+34.2% above sector average
Key checks
Key Insights
- Exelixis's operating cash flow has grown for 3 consecutive years.
- 5-year CAGR of +33.4%, indicating consistent growth.
- In FY2025, operating cash flow increased 26.3% year-over-year.
- Ranks #22 out of 216 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.33 (safe zone, above 2.9 threshold)
- Strong profit margin: 29.6%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 31.4%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $884.3M | +26.3% |
| FY2024 | $700.0M | +110.0% |
| FY2023 | $333.3M | +59.5% |
| FY2022 | $209.0M | -60.3% |
| FY2021 | $527.0M | +152.2% |
| FY2020 | $209.0M | -60.3% |
| FY2019 | $527.0M | +150.4% |
| FY2018 | $210.4M | +27.0% |
| FY2017 | $165.6M | -21.3% |
| FY2016 | $210.4M | +248.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026